EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) has announced the commencement of an underwritten public offering of $150 million of shares of its common stock. The company also intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $22.5 million of shares of EyePoint’s common stock.
The net proceeds from the offering will be used to advance clinical development of Duravyu™ for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), as well as to support the company’s earlier stage pipeline development initiatives and for general corporate purposes.
Duravyu™, EyePoint’s lead product candidate, is an innovative investigational sustained delivery treatment for VEGF-mediated retinal diseases. It combines vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), in next-generation bioerodible Durasert E™ technology. The product is currently being evaluated in two phase 3 pivotal trials for wet AMD with data anticipated in mid-2026. First patient dosing in the pivotal phase 3 clinical trials in DME is expected in the first quarter of 2026.
EyePoint is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation. The company is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Vorolanib, which is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong, and Taiwan.
The press release also includes information about the securities being offered by the company pursuant to an automatically effective shelf registration statement on Form S-3.
EyePoint's stock is listed on the NASDAQ and the offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Joint book running managers for the offering include J.P. Morgan, Jefferies, Citigroup, and Guggenheim Securities. As a result of these announcements, the company's shares have moved -1.53% on the market, and are now trading at a price of $11.55. If you want to know more, read the company's complete 8-K report here.
